ITRM – Iterum Therapeutics Plc
ITRM — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
5.85
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.1
EPS Last/This Y
EPS This/Next Y
0.35
Price
0.03
Target Price
Analyst Recom
3
Performance Q
-91.64
Upside
N/A
Beta
3.42
Ticker: ITRM
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-20 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-04-23 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-04-24 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-04-27 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-04-28 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-04-29 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-04-30 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-01 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-04 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-05 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-06 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-07 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-08 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-11 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-12 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-13 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-14 | ITRM | 0.03 | N/A | N/A | 0 |
| 2026-05-15 | ITRM | 0.03 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
No data found
No data found
Last Quarter Act. EPS
-0.2
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.1
Insider Transactions
1.46
Institutional Transactions
Beta
3.42
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
15
Growth Score
22
Sentiment Score
1
Actual DrawDown %
99.9
Max Drawdown 5-Year %
-99.9
Target Price
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-0.72
Average EPS Est. Cur. Y
-0.66
EPS Next Y. (Est.)
-0.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
337.7
Return on Equity vs Industry %
354.2
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.33
EBIT Estimation
9.2
No data found for ITRM
Iterum Therapeutics plcSector: Healthcare
Industry: Biotechnology
Employees: 9
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
ITRM
Latest News
—
Caricamento notizie per ITRM…
stock quote shares ITRM – Iterum Therapeutics Plc Stock Price stock today
news today ITRM – Iterum Therapeutics Plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ITRM – Iterum Therapeutics Plc yahoo finance google finance
stock history ITRM – Iterum Therapeutics Plc invest stock market
stock prices ITRM premarket after hours
ticker ITRM fair value insiders trading